Exobozan
Antineoplastic, tyrosine kinase inhibitor, indicated as an oral treatment for patients with advanced renal cancer or as a second-line treatment for hepatocellular carcinoma.
Therapeutic Area
Oncology
Active Ingredient
Cabozantinib
Line
Oncology
Dosage forms
20 mg, 40 mg and 60 mg x 30 coated tablets
